Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Clinical Spectrum and Outcomes of Anti-metabotropic glutamate receptor 5 Encephalitis in Chinese Patients: A Case Report and Literature Review

Provisionally accepted
  • Department of Neurology, First Hospital, Peking University, Beijing, China

The final, formatted version of the article will be published soon.

Background: Anti-metabotropic glutamate receptor 5 (mGluR5) encephalitis is a rare autoimmune disorder that targets the metabotropic glutamate receptor. It is frequently linked to limbic encephalitis and paraneoplastic syndromes, such as Ophelia syndrome associated with Hodgkin lymphoma. Due to its rarity, the complete clinical spectrum and regional variations of this condition remain inadequately understood. Case Description: We present a case of a 39-year-old Chinese male diagnosed with anti-mGluR5 encephalitis. The patient initially presented with persistent fever, which later progressed to seizures, psychosis, apathy, drowsiness, and memory impairment. Brain imaging findings were unremarkable, while electroencephalogram revealed predominant beta wave activity. Cerebrospinal fluid (CSF) analysis showed pleocytosis and elevated protein levels. Both serum and CSF tested strongly positive for mGluR5 antibodies (titers 1:160 and 1:640), with no other autoantibodies detected. A thorough evaluation revealed no evidence of an underlying tumor. Symptom resolution was rapid following intravenous methylprednisolone pulses, with sustained remission achieved through rituximab therapy combined with a gradual tapering of steroids over one year follow-up. Literature Review: In 18 Chinese patients, the median age was 36 years (range 7–60), with 61% being male (11/18). Only 17% (3/18) had associated tumors, including two cases of teratomas and one of gangliocytoma. The clinical manifestations were highly diverse, with headache (44.4%), irritability/sleepiness (38.9%), and seizures (38.9%) being the most prevalent. Additional symptoms included hallucinations (33.3%), fever (27.8%), memory impairment (27.8%), dystonia (22.2%), and consciousness disorders (22.2%). Antibody analysis showed that 94.4% of patients were serum mGluR5-positive, 61.1% had mGluR5-antibodies in CSF, and 55.5% tested positive in both. MRI anomalies were identified in 72.2% of patients, typically affecting the temporal/insular lobes. Immunotherapy, consisting of steroids, intravenous immunoglobulin and/or immunosuppressant, was administered to 94.4% patients, resulting in favorable outcomes for 17 cases. Conclusion: This study highlights that anti-mGluR5 encephalitis in Chinese patients exhibits significant clinical heterogeneity and a notably low association with tumors (17%), contrasting with higher rates reported elsewhere. Immunotherapy, including steroids and potentially rituximab, appears highly effective. Clinicians should be aware of the broad symptom spectrum and the relatively low paraneoplastic risk in this population. Vigilance for tumors, especially teratomas and neural tumors, remains essential.

Keywords: Anti-mGluR5 encephalitis, metabotropic glutamate receptor 5, autoimmune encephalitis, Neuroimmune disease, glucococorticoids

Received: 30 Jun 2025; Accepted: 28 Oct 2025.

Copyright: © 2025 Niu, Chen, Wang, Yu, Jingru, Liu, Guo, Zhang, Gao and Hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Siwei Chen, siwei_chen1993@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.